Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

Cancer discovery - 1 Jan 2017

Brown Jessica S, O'Carrigan Brent, Jackson Stephen P, Yap Timothy A

Abstract excerpt

Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers. Herein, we detail how cellular DDR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Repair
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 gene

Share to Genetic Predisposition to Disease

Share to Mutation

Share to Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 28003236
DOI: 10.1158/2159-8290.CD-16-0860
PMCID: PMC5300099

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.PMID 28003236Read ↗

Targeting DNA damage response pathways in cancer.Semantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response in CancerSemantic proximity Read ↗

Evolving DNA repair synthetic lethality targets in cancerSemantic proximity Read ↗

Targeting the DNA damage response in oncologySemantic proximity Read ↗

DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directionsSemantic proximity Read ↗

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer TherapySemantic proximity Read ↗

The DNA Damaging Revolution: PARP Inhibitors and BeyondSemantic proximity Read ↗

Targeting the DNA Damage Response for Cancer TherapySemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.Semantic proximity Read ↗

Directing the use of DDR kinase inhibitors in cancer treatment.Semantic proximity Read ↗

Molecular Pathways: Targeting PARP in Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.